Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies

被引：89

作者：

Witzig T.E. ^{[1
]}

Kaufmann S.H. ^{[1
]}

机构：

[1] Mayo Clinic, Rochester, MN 55905

来源：

Current Treatment Options in Oncology | 2006年 / 7卷 / 4期

关键词：

Rapamycin; Hematologic Malignancy; Everolimus; Mantle Cell Lymphoma; Acute Myelogenous Leukemia;

D O I：

10.1007/s11864-006-0038-1

中图分类号：

学科分类号：

摘要：

The phosphatidylinositol 3-kinase (PI3-K)/mammalian target of rapamycin (mTOR) signal transduction pathway integrates signals from multiple receptor tyrosine kinases to control cell proliferation and survival. Key components of the pathway are the lipid kinase PI3-K, the small guanosine triphosphate-binding protein Rheb, and the protein kinases Akt and mTOR. Important natural inhibitors of the pathway include the lipid phosphatase PTEN and the tuberous sclerosis complex. Several components of this pathway are targeted by investigational antineoplastic agents. Rapamycin (sirolimus), the prototypic mTOR inhibitor, exhibits activity in acute myeloid leukemia. Three rapamycin analogs, temsirolimus, everolimus, and AP23573, are in clinical trials for various hematologic malignancies. Temsirolimus has produced a 38% overall response rate in relapsed mantle cell lymphoma, and AP23573 has demonstrated activity in acute leukemia. Everolimus is undergoing clinical testing in lymphoma (Hodgkin and non-Hodgkin) and multiple myeloma. In addition, perifosine, an inhibitor of Akt activation that exhibits substantial antimyeloma activity in preclinical models, is being examined in relapsed multiple myeloma. Based on results obtained to date, it appears that inhibitors of the PI3-K/mTOR pathway hold promise as single agents and in combination for hematologic malignancies. Copyright © 2006 by Current Science Inc.

引用

页码：285 / 294

页数：9

共 59 条

[31]

Ali I.U., Schriml L.M., Dean M., Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity, J Natl Cancer Inst, 91, pp. 1922-1932, (1999)

[32]

Brognard J., Clark A.S., Ni Y., Dennis P.A., Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation, Cancer Res, 61, pp. 3986-3997, (2001)

[33]

Granville C.A., Memmott R.M., Gills J.J., Dennis P.A., Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway, Clin Cancer Res, 12, pp. 679-689, (2006)

[34]

Vlahos C.J., Matter W.F., Hui K.Y., Brown R.F., A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), J Biol Chem, 269, pp. 5241-5248, (1994)

[35]

Uddin S., Hussain A.R., Al-Hussein K.A., Et al., Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells, Clin Cancer Res, 11, pp. 3102-3108, (2005)

[36]

Shi Y., Yan H., Frost P., Et al., Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade, Mol Cancer Ther, 4, pp. 1533-1540, (2005)

[37]

Hideshima T., Catley L., Yasui H., Et al., Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells, Blood, 107, pp. 4053-4062, (2006)

[38]

Crul M., Rosing H., de Klerk G.J., Et al., Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours, Eur J Cancer, 38, pp. 1615-1621, (2002)

[39]

Van Ummersen L., Binger K., Volkman J., Et al., A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer, Clin Cancer Res, 10, pp. 7450-7456, (2004)

[40]

Sehgal S.N., Baker H., Vezina C., Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization, J Antibiot (Tokyo), 28, pp. 727-732, (1975)

← 1 2 3 4 5 6 →